Celera Genomics has gotten out of the drug-development business. The Rockville-based biotechnology company said Wednesday it sold a small-molecule drug program for the treatment of autoimmune diseases to German pharmaceutical giant Schering AG.
Washington Business Journal
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Garmin to Develop Wearables for Remote Patient Monitoring
Garmin notes that the use of wearables as health and medical tools is rapidly evolving and the company is “committed to the development of wearables that can lead to the detection of serious health conditions.”
CMS Report: Retail Drug Spending Slowed in 2017
CMS said the catalysts for slower retail drug spending include slower growth in the number of prescriptions dispensed and slower volume growth of expensive drugs.
FDAnews Drug Daily Bulletin
CELERA SELLS DRUG PROGRAM TO SCHERING AG
June 23, 2006
